RecruitingPhase 1NCT07584954
Phase I, Open-labeled, Dose-escalation, Dose-expansion Study Evaluating the Safety, Tolerance, Pharmacokinetics, and Activity of IUAb190708 in Patients With Advanced or Recurrent Solid Tumors
Sponsor
Jun Zhou
Enrollment
90 participants
Start Date
Jun 18, 2024
Study Type
INTERVENTIONAL
Conditions
Summary
This study is to evaluate a novel cytotoxic anti-PD-L1, IUAb190708, for the treatment of tumor
Eligibility
Min Age: 18 YearsMax Age: 75 Years
Plain Language Summary
Simplified for easier understanding
This clinical trial is studying a drug called IUAb190708, a cytotoxic antibody for people with solid tumor cancer and solid tumor cancer treatment with immunotherapy. The study is currently recruiting participants at 6 locations. People eligible for this study include aged 18 Years to 75 Years.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGIUAb190708, a cytotoxic antibody
a novel cytotoxic anti-PD-L1 antibody
Locations(6)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07584954
Related Trials
Safety, Tolerability, and Preliminary Antitumor Activity of Cationic Peptide-IL22BP mRNA in Advanced Solid Tumors
NCT075836541 location
A First in Human Study of PLT012 in Participants With Solid Tumor Cancers
NCT073375254 locations
BEACON-1: Study of AVZO-103 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Urothelial Cancer or Other Solid Tumors (AVZO-103-1001)
NCT0719351111 locations
Metronomic Gemcitabine, Mitomycin C, and Thalidomide for Advanced Solid Tumors
NCT076715341 location
Effect of Meal Timing During Cancer Treatment in Patients in Alaska: A Randomized Clinical Trial
NCT068021721 location